People News: Biogen Idec, Noven Pharmaceuticals and Corbett Accel

Share this content:
James Mullen, president and CEO of Biogen Idec, will retire from his position effective June 8, the company said. Mullen will also retire as director of the company's board at the Biogen annual shareholder meeting this year. Biogen said it has initiated a search for a successor.

Noven Pharmaceuticals hired Andrew Panagy as VP, marketing & sales. Prior to joining Noven, Panagy served as VP and global business manager of Wyeth's Women's Health Care business unit, with principal responsibility for its menopausal product portfolio, and as Wyeth's VP, US marketing – Women's Health Care. Panagy will be responsible for all marketing and sales activities at Noven Therapeutics and Novogyne Pharmaceuticals, Noven's joint venture with Novartis. He will report to Jeffrey Eisenberg, Noven's president and CEO and Novogyne's president.

Geoffrey Melick, formerly of Corbett Accel, joined Tribune Company as SVP health, in which role he will head health advertising and oversee Melick was EVP/interactive marketing and e-innovation at Corbett Accel.

Share this content:
Scroll down to see the next article